Trial · NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938, Phase 3, Recruiting, Hoffmann-La Roche
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma. Trials, record NCT07555938. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07555938
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- NCT number
- NCT07555938
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 380 participants, estimated
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib
- First posted
- 2026-04-29
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate | Up to 1 year after the last participant is randomized | |
| Primary | Progression-Free Survival (PFS) | Up to 5 years after the last participant is randomized | |
| Secondary | Very Good Partial Response (VGPR) or Better Rate | Up to 5 years after the last participant is randomized | |
| Secondary | Overall Survival (OS) | Up to 5 years after the last participant is randomized | |
| Secondary | Change in Disease Symptoms as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20) | From baseline to Month 6 | Primary domains: fatigue, pain, physical functioning, cognitive functioning and global health status. |
| Secondary | Overall Response Rate (ORR) | Up to 5 years after the last participant is randomized | |
| Secondary | Complete Response (CR) Rate | Up to 5 years after the last participant is randomized | |
| Secondary | Time to Response (TTR) | Up to 5 years after the last participant is randomized | |
| Secondary | Time to Best Response (TTBR) | Up to 5 years after the last participant is randomized | |
| Secondary | Duration of Response (DOR) | Up to 5 years after the last participant is randomized |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07555938
GET https://conductscience.org/api/trials/v1/NCT07555938/registered?page=2